PTJ
KNTE

Paul Tudor Jones’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Paul Tudor Jones’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40,373
Closed -$1.61M – 1920
2020
Q4 		$1.61M Buy
+40,373
New +$1.62M 0.05% 510

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paul Tudor Jones's KNTE Position: Q1 2021 in Review

Paul Tudor Jones sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2021, closing a stake of 40,373 shares — an estimated $1.61M sold.

Paul Tudor Jones first reported a position in KNTE in Q4 2020 and held it in 1 quarter. The position peaked at $1.61M in Q4 2020. 62 funds tracked by Wall St. Rank hold KNTE as of Q1 2021.

  • Paul Tudor Jones reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Paul Tudor Jones sold 40,373 Kinnate Biopharma Inc. Common Stock shares in Q1 2021, an estimated $1.61M.
  • Paul Tudor Jones first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 1 quarter.
  • Paul Tudor Jones's Kinnate Biopharma Inc. Common Stock position peaked at $1.61M in Q4 2020.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2021.

Based on Tudor Investment Corp's 13F filing for Q1 2021, filed 17 May 2021.